Veritas Pharma (VRT.C) moved further along the trail to commercialization when the company announced that it is currently working with its research arm, Cannevert Therapeutics to design and implement the first clinical trials of cannabis strains targeting pain.
According to the news release, top contract research organizations with clinical experience in evaluating cannabis and its impact on pain are being vetted for cost estimates and timelines.
Company CEO, Dr. Lui Franciosi commented, “Cannevert’s chemical and animal studies have identified suitable strains that warrant immediate human trials, which will be done to the highest standards at institutes of high repute.”
Both Veritas and Cannevert expect to implement these clinical trials this year.
Once a research partner has been identified and a contract negotiated, a formal announcement will be made.
FULL DISCLOSURE: Veritas Pharma is an EQUITY.GURU client.Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.